Inhibitory effects of topical cyclosporine A 0.05 % on immune-mediated corneal neovascularization in rabbits

Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial

(2012) Constantinos Petsoglou et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction

(2012) Pinnita Prabhasawat et al.   CORNEA

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis

(2012) Seydi Okumus et al.   BMC Ophthalmology

Prospective, Randomized Study of the Efficacy of Systemic Cyclosporine in High-Risk Corneal Transplantation

(2011) Jun Shimazaki et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model

(2011) Beatrice Bourghardt Peebo et al.   ANGIOGENESIS

Treatments for Corneal Neovascularization: A Review

(2011) Deepak Gupta et al.   CORNEA

Efficacy of topical cyclosporine for the treatment of ocular rosacea

(2009) Barry A. Schechter et al.   ADVANCES IN THERAPY

Topical Bevacizumab in the Treatment of Corneal Neovascularization

(2009) Mohammad H. Dastjerdi   ARCHIVES OF OPHTHALMOLOGY

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

(2009) Yanyan Koenig et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY